ストックスクリーナーアプリを入手
0.501
0.20%
-0.001
アフターアワーズ：
.50
-0.001
-0.20%
前日終値:
$0.502
開ける：
$0.59
24時間の取引高:
227.18K
Relative Volume:
5.28
時価総額：
$20.92M
収益：
-
当期純損益:
$-563.30K
株価収益率:
-2.51
EPS:
-0.1996
ネットキャッシュフロー:
$-22.23M
1週間 パフォーマンス:
-21.72%
1か月 パフォーマンス:
-10.47%
6か月 パフォーマンス:
-48.88%
1年 パフォーマンス:
-73.49%
1日の値動き範囲:
$0.4999
$0.5909
1週間の範囲:
$0.4702
$0.7033
52週間の値動き範囲:
$0.4702
$2.37
Promis Neurosciences Inc Stock (PMN) Company Profile
名前
Promis Neurosciences Inc
セクター
電話
416-847-6898
住所
SUITE 200, 1920 YONGE STREET, TORONTO
PMN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.501 | 20.92M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc (PMN) 最新ニュース
ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga
ProMIS Neurosciences (PMN): Maxim Group Initiates Coverage with Buy Rating | PMN Stock News - GuruFocus
Maxim Group Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation - Nasdaq
ProMIS Neurosciences Announces First Quarter 2025 Financial Resu - GuruFocus
ProMIS Neurosciences (PMN) Advances Alzheimer's Clinical Program - GuruFocus
ProMIS Neurosciences Inc. SEC 10-Q Report - TradingView
ProMIS Neurosciences Announces First Quarter 2025 Financial Results - GlobeNewswire
Multiple System Atrophy Treatment Algorithm, Clinical Trials - openPR.com
Parkinson’s vaccine selectively targets pathogenic αSyn - BioWorld MedTech
ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa
ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India
Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN
ProMIS Neurosciences’ (PMN) Buy Rating Reaffirmed at Guggenheim - Defense World
ProMIS Neurosciences Reports 2024 Financial Turnaround - TipRanks
ProMIS Neurosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PROMIS NEUROSCIENCES Earnings Results: $PMN Reports Quarterly Earnings - Nasdaq
ProMIS Neurosciences Inc. (PMN) reports earnings - Quartz
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - The Manila Times
Form 424B5 ProMIS Neurosciences - StreetInsider
ProMIS Neurosciences Inc. SEC 10-K Report - TradingView
ProMIS Neurosciences Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
ProMIS to present neurodegenerative disease research By Investing.com - Investing.com Australia
New Diagnostics And Treatments Transform Neurodegenerative Disease Care - Evrim Ağacı
ProMIS to present neurodegenerative disease research - Investing.com India
ProMIS Neurosciences Showcases Preclinical Data on - GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference - Yahoo Finance
ProMIS Neurosciences (PMN) Expected to Announce Quarterly Earnings on Monday - Defense World
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart
Multiple System Atrophy Market to Reach New Heights in Growth - openPR
ProMIS to present vaccine data at neurology meeting By Investing.com - Investing.com Australia
ProMIS to present vaccine data at neurology meeting - Investing.com India
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - The Manila Times
ProMIS Neurosciences to Present Preclinical Data on Computational Vaccine Development for Neurodegenerative Diseases at AAN Annual Meeting - Nasdaq
ProMIS Neurosciences Showcases Preclinical Data on Platform - GlobeNewswire
PROMIS NEUROSCIENCES Earnings Preview: Recent $PMN Insider Trading, Hedge Fund Activity, and More - Nasdaq
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewswire
ProMIS Neurosciences’ (PMN) “Buy” Rating Reiterated at Guggenheim - Defense World
ProMIS Neurosciences begins Alzheimer’s trial dosing - Investing.com India
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial - TipRanks
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
ProMIS Neurosciences begins Alzheimer’s trial dosing By Investing.com - Investing.com South Africa
ProMIS Neurosciences begins Alzheimer's trial dosing - Investing.com
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for ... - The Bakersfield Californian
Multiple System Atrophy Clinical Trials and Pipeline 2025: EMA, - openPR
Promis Neurosciences Inc (PMN) 財務データ
収益
当期純利益
現金流量
EPS
4.10%
大文字化:
|
ボリューム (24 時間):